Pegazofermin Enters Phase 3 ENLIGHTEN Clinical Trial Program for MASH
The 2 phase 3 trials in the 89bio ENLIGHTEN clinical trial program will evaluate the safety and efficacy of the FGF21 analog in MASH, fibrosis.
First Issue of Patient Care Online Digital Edition Goes Live
The inaugural digital issue of Patient Care focuses on the antiobesity and type 2 diabetes medications, semaglutide and tirzepatide.
Risk of Stroke Mitigated by Even Low Levels of Physical Activity
Even activity levels considered "insufficient" by guideline standards were found protective against stroke in this new systematic review and meta-analysis.
Early Detection of CKD Progression in Primary Care: Daily Dose
Your daily dose of the clinical news you may have missed.
Could Prior Authorization Work Win its Own CPT Code?
A CPT code for time spent petitioning insurance companies to approve patient prescriptions has been proposed before; sentiment was not unanimous.
Tapinarof Cream 1.0% Effective for Atopic Dermatitis in Persons with Skin of Color: ADORING Phase 3 Program
Study participants self-identified as Black, White, or Asian and significant proportions reached improvement of ≥75% in EASI in both in ADORING 1 and ADORING-2.
Nirsevimab 90% Effective Against RSV Hospitalization among Infants, According to New CDC Data
Findings support current CDC recommendations that all infants should be protected by maternal RSV vaccination or infant receipt of nirsevimab.
Semaglutide Lowers CKD-Related Events in Persons with T2D, CKD: Daily Dose
Melatonin Implicated in 11K ED Visits for Infants, Children Over 4 Years: MMWR
Melatonin products, particularly flavored gummies and tablets, were documented in 7 out of 10 ED visits for unsupervised medication exposure in children aged ≤5 years.
Semaglutide 2.4 mg (Wegovy) Wins Expanded Indication to Include Reduced Risk of MACE
The label expansion for semaglutide, based on the SELECT trial, includes data showing reduced risk of CV death of 15% and of death from any cause of 19%.
New Data Show High Prevalence of Dyslipidemia in American Indian Youth
Few participants with dyslipidemia received lipid-lowering medications despite high prevalence, reported authors of the Strong Family Heart Study.
Underrepresentation of Individuals with CKD in CV Medication Trials Found Persistent Over 2 Decades
Authors: Exclusion of people with CKD from CV medication trials has left significant gaps in understanding the effectiveness of these drugs in a highly vulnerable population.
Weak in the Legs and Lips: Seen in the ED
A man in his eighties presents to the ED after 1 week of persistent bilateral leg weakness and dysgeusia that has not worsened. What's your Dx?
Migraine, Persistent VMS Tied to Higher Risk of CVD, Stroke: Daily Dose
Lilly Investigational Alzheimer Agent Donanemab Phase 3 Findings Under FDA Review
The surprise request for review of the phase 3 TRAILBLAZER-ALZ-2 clinical trial findings will delay the original PDUFA timing beyond first quarter 2024.
Initiating Opioid Therapy for Chronic Pain: Does Which Medication Matter?
A new study compared opioid utilization trajectories of patients initiating tramadol, hydrocodone, and oxycodone. Key takeaways at-a-glance, here.
Plastic Debris Detected in Carotid Plaque Linked to Higher Risk for MI, Stroke, Death
Patients who had microplastics and nanoplastics in their carotid plaque were at more than a fourfold risk for MI, stroke, or death compared to those who did not, according to a new study.
Boehringer Ingelheim Will Cap Out of Pocket Costs for Inhalers at $35 per Month
The monthly out of pocket cap applies to all BI inhalers and goes into effect on June 1, 2024.
Neffy May be Safe, Effective for Treatment of Urticaria Flares: Daily Dose
Novo Nordisk Shares Early Findings for Novel Oral Antiobesity Agent
The novel unimolecular pill amycretin combines a GLP-1 and an amylin agonist and led to weight loss of 13% at 12 weeks in a phase 1 trial that just concluded, the company said.